Talia Flanagan

Abstract ID: 13Evaluation of the need for and criteria within a paediatric biopharmaceutics classification system: Results of a survey

Hannah Batchelor, Terry B. Ernest, Talia Flanagan, 2016 .

Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms

Talia Flanagan, Andre Hermans, Andreas M. Abend, 2017, The AAPS Journal.

Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products

Talia Flanagan, Filippos Kesisoglou, Arzu Selen, 2020, The AAPS Journal.

Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.

Talia Flanagan, Amitava Mitra, Sandra Suarez-Sharp, 2020, Journal of pharmaceutical sciences.

Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.

Talia Flanagan, Anette Müllertz, Filippos Kesisoglou, 2016, Journal of pharmaceutical sciences.

Dissolution Highlights from the 2015 AAPS Annual Meeting in Orlando

Talia Flanagan, Vivian A. Gray, Nikoletta Fotaki, 2016 .

In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

Talia Flanagan, Clive G. Wilson, Mai Anh Nguyen, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives

Talia Flanagan, Andreas M. Abend, Xavier Pepin, 2019, Pharmaceutics.